Rapid onset of tolerance to beta-agonist bronchodilation.

Respir Med

Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand.

Published: May 2005

Introduction: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This is easily demonstrated if dilation is tested following methacholine challenge. It is not known how quickly tolerance develops or how long it lasts after stopping beta-agonist therapy.

Methods: Ten subjects with stable asthma were studied. Following 2 weeks without beta-agonists, methacholine was inhaled to induce a 20% reduction in FEV1. The response to inhaled salbutamol (100, 100, 200 microg at 5-min intervals) was then measured. This procedure was repeated 24 h after one dose and 24 h after 3, 7 and 14 days of inhaled formoterol 12 microg twice daily, and 3 and 5 days after formoterol was discontinued. Unscheduled use of beta-agonists was not permitted.

Results: Bronchodilator tolerance, assessed by a reduction of the area under the salbutamol dose-response curve, occurred after 1 dose of formoterol (28% reduction, 95% CI 12, 45%), increased up to 1 week and plateaued between 1 and 2 weeks (58% reduction, 95% CI 38, 78%). Three days after stopping formoterol, the response to salbutamol was similar to baseline (12% reduction, 95% CI -9, 33%). The first dose of formoterol provided significant bronchoprotection to methacholine (1.6 doubling doses, P=0.007). This diminished with regular treatment and by 2 weeks the PD20 methacholine was not significantly different to baseline.

Conclusions: Bronchodilator tolerance occurs after a single dose and reaches a maximum after 1 week of regular formoterol. Sensitivity recovers 3 days after stopping treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmed.2004.10.014DOI Listing

Publication Analysis

Top Keywords

reduction 95%
12
bronchodilator tolerance
8
dose formoterol
8
days stopping
8
formoterol
6
tolerance
5
reduction
5
rapid onset
4
onset tolerance
4
tolerance beta-agonist
4

Similar Publications

Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous trials for priapism prevention have failed to demonstrate clear efficacy. We conducted a randomized, controlled, double-blind phase 2 feasibility trial comparing fixed moderate-dose hydroxyurea plus placebo (usual care arm) versus fixed moderate-dose hydroxyurea plus tadalafil (experimental arm) in 64 men (18- 40 years) with at least three episodes of SCA-related priapism in the past 12 months.

View Article and Find Full Text PDF

Background: There were 2227 drug-related deaths in Germany in 2023, corresponding to a rise of 12% over the previous year and a doubling over the course of a decade. Approximately 60% of these deaths were related to opioid consumption. In this narrative review, we discuss whether take-home naloxone (THN) might lower the mortality of persons with opioid dependency.

View Article and Find Full Text PDF

Design: Platelet-rich plasma (PRP) is a popular treatment option in managing chronic tendinopathies, although the literature is inconsistent, mainly because of significant heterogeneity in patient populations. Patients who failed conservative management may respond differently than those who have not undergone first-line treatment. This systematic review and meta-analysis aimed to evaluate the efficacy of PRP injections in reducing pain and improving function in patients with chronic tendinopathy who failed conservative treatment.

View Article and Find Full Text PDF

Reduction of the germole-ligated sandwich complexes [(η5-CpGe)M(η5-Cpttt)]2 (1M, M = Y, Gd, Dy) with one or two equivalents of KC8/2.2.2-cryptand produces [(η5-CpGe)M(η5-Cpttt)2]- (2M) and [(η5-CpGe)M(η5-Cpttt)2]2- (3M), respectively, as salts of [K(2.

View Article and Find Full Text PDF

Purpose: Several risk factors for adjacent segment disease (ASD) after posterior lumbar interbody fusion (PLIF) have been reported. High pelvic incidence (PI) has been identified as risk factors for L4 anterior slip in cases of lumbar degenerative spondylolisthesis. Correcting the slip with L4-L5 fixation merely restores the lumbar alignment, but the PI itself remains unchanged.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!